Head-to-head evidence
Bexagliflozin vs Rongliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison was statistically significant in favor of bexagliflozin. The grade is moderate because HbA1c is a surrogate measure rather than a hard clinical outcome.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
Rongliflozin
Developed by Sunshine Lake Pharma
NCT05427682 · Phase 1 · completed
A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Rongliflozin's landscape